Paper Details

  1. Home
  2. Paper Details

Management of myelofibrosis after ruxolitinib failure.

Author: BosePrithviraj, VerstovsekSrdan

Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Ruxolitinib is a JAK1/2 inhibitor that improves splenomegaly and symptoms in myelofibrosis patients, providing a survival benefit for those with intermediate-2/high risk. However, it can cause cytopenias and does not address the risk of leukemic transformation. Fedratinib, a JAK2 inhibitor, is now approved for patients who don't respond well to ruxolitinib, but further research is needed. Other JAK inhibitors and new therapies are being investigated for those who fail ruxolitinib treatment or have sub-optimal responses.
Paper Details　
Original Abstract of the Article :
Over the last decade, the Janus kinase1/2 (JAK1/2) inhibitor ruxolitinib has emerged as a cornerstone of myelofibrosis (MF) management. Ruxolitinib improves splenomegaly and symptoms regardless of driver mutation status, and confers a survival advantage in patients with intermediate-2/high risk MF. ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/32297800

データ提供：米国国立医学図書館（NLM）

Navigating the Shifting Sands of Myelofibrosis Treatment

Myelofibrosis, a bone marrow disorder, is a challenging condition, like a shifting desert landscape that requires careful navigation. This study explores the management of myelofibrosis after ruxolitinib, a JAK1/2 inhibitor, has failed to provide a durable response. The authors discuss the challenges of treating myelofibrosis in the setting of ruxolitinib resistance, highlighting the limited treatment options and the need for further research to develop more effective therapies.

A Shifting Desert Landscape: Managing Myelofibrosis Resistance

The study highlights the need for novel therapeutic approaches to manage myelofibrosis in patients who have developed resistance to ruxolitinib. While new therapies, such as fedratinib, are being explored, further research is crucial to find effective treatment strategies for this challenging condition.

Finding a Sustainable Oasis: Evolving Treatments for Myelofibrosis

This research underscores the importance of ongoing research and development of new therapies for myelofibrosis. By exploring novel approaches and understanding the mechanisms of resistance, healthcare providers can provide more effective treatments for patients with this complex condition.

Dr. Camel's Conclusion

The desert of myelofibrosis treatment is vast and unforgiving, with the emergence of drug resistance posing a significant challenge. This study highlights the urgent need for new therapeutic strategies, reminding us that the quest for effective treatments must continue.

Date :
  1. Date Completed 2021-04-27
  2. Date Revised 2021-12-04
Further Info :

Pubmed ID

32297800

DOI: Digital Object Identifier

NIHMS1621231

Related Literature

Article Analysis
・Effects of momelotinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.